Whole Genix wins the 2018 Mediterráneo Excellente Prize for Medical Innovation Blog Post

The company Whole Genix, headquartered in the Barcelona Science Park, received the 2018 Mediterráneo Excelente Prize in the Medical Innovation category. This award was received during the gala marking the IV edition of these prizes, held on Friday in Hotel Arts in Barcelona. With these awards, the editorial group El Suplemento aims to assess and highlight entrepreneurial, scientific and cultural talent, as well as social and charity initiatives undertaken by companies, institutions and professionals from the Mediterranean Arc.


Fundación GAEM launches its inclusive charity campaign ‘Yo Doy mis Pasos’ Blog Post

GAEM Foundation, headquartered in the Barcelona Science Park, launches its inclusive charity campaign Yo Doy mis Pasos’ [I give my steps], which aims to raise 1 million euros to promote biomedical research in multiple sclerosis, an incurable neurodegenerative disease which affects around 8,000 people in Catalonia and 50,000 in Spain. It is also the second biggest cause of disability in young people in developed countries after road accidents.


The UTOX-PCB Unit renews and extends its certificate of compliance with Good Laboratory Practices Blog Post

The Unit of Experimental Toxicology and Ecotoxicology of the Barcelona Science Park has renewed its certificate of compliance with Good Laboratory Practices (GLP) for the conduct of all types of in vivo and in vitro toxicology studies, mutagenicity studies and ecotoxicity studies involving medicinal products for human and veterinary use, medical devices and cosmetics. The site has also extended the certification for microbiological studies of bactericide efficiency. 


IBEC and IRB Barcelona are awarded funding from the Spanish Association Against Cancer Blog Post

Yesterday, coinciding with World Cancer Research Day (WCRD), which takes place on 24 September each year, theSpanish Association Against Cancer (Asociación Española Contra el Cáncer, AECC) celebrated the 2018 AECC Cancer Research Grants awards ceremony. Among the proposals selected are two projects from the Institute for Bioengineering of Catalonia (IBEC) and five from the Institute for Research in Biomedicine (IRB Barcelona), which is based at PCB.


UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs Blog Post

The Unit of Experimental Toxicology and Ecotoxicology of the Barcelona Science Park (PCB) is taking part in a consortium that aims to develop and provide preclinical checks for new candidates for first-in-class cancer drugs. The project, called Preclinonco, has just received an injection of nearly 350,000 euros from the Retos-Colaboración 2017 program, promoted by the Ministry of Science, Innovation and Universities with ERDF funding.


IRB Barcelona has been awarded two ERC Proof of Concept to tackle colon cancer and cardiotoxicity Blog Post

Eduard Batlle and Angel R. Nebreda, ICREA researchers at the Institute for Research in Biomedicine (IRB Barcelona), have been awarded an ERC Proof of Concept grant. Over the next 18 months and supported by 150,000 euros of funding each, they will devote their efforts to developing tools with potential therapeutic applications in the field of oncology. This is the second time that these scientists have received an ERC PoC grant.


Dr. Eliandre de Oliveira, cientific leader of the B·Debate on clinical proteomics Blog Post

World leaders in proteomics will meet at CaixaForum Barcelona on 7 and 8 November in an event held by B·Debate, an initiative by Biocat and Obra Social ‘la Caixa’, co-organized in this edition by Barcelona Science Park (PCB), ProteoRed-ISCIII, Bellvitge Biomedical Research Institute (IDIBELL), Centre for Genomic Regulation (CRG) and Vall d’Hebron Institute of Oncology (VHIO). Four experts of renowned prestige in this field –including Dr. Eliandre de Oliveira, head of the PCB’s Proteomics Platform– will lead the debate.


Researchers design a nano-carrier to release drugs into damaged cells Blog Post

A team headed by the ICREA researcher Manuel Serrano at the Institute for Research in Biomedicine (IRB Barcelona), located in the Barcelona Science Park (PCB), has designed a drug encapsulation system that selectively targets senescent cells. The study, published in EMBO Molecular Medicine, paves the way for therapeutic approaches to eliminate these zombi cells in many diseases, such as pulmonary fibrosis and cancer. This is currently a central goal for many pharmaceutical companies, among them the one co-founded by Manuel Serrano himself Senolytic Therapeutics, based in PCB and in Boston.